A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2021-08-25
Target enrollment:
Participant gender:
Summary
A Phase I/2 multi-center open-label study of BGB324 (bemcentinib) in combination with
erlotinib in participants with Stage IIIb or Stage IV non-small cell lung cancer. Bemcentinib
is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase
receptor which is connected with poor prognosis and acquired resistance to therapy.